Moleculin Biotech (NASDAQ:MBRX) Trading 0.8% Higher – Here’s What Happened

Moleculin Biotech, Inc. (NASDAQ:MBRX) traded up 0.8% during trading on Friday . The stock traded as high as $2.48 and last traded at $2.42. 95,431 shares were traded during mid-day trading, an increase of 4% from the average session volume of 92,002 shares. The stock had previously closed at $2.40.

Analyst Ratings Changes

A number of research analysts recently issued reports on MBRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Stock Up 0.8%

The business’s fifty day simple moving average is $2.63 and its two-hundred day simple moving average is $6.01. The company has a market cap of $12.92 million, a price-to-earnings ratio of -0.07 and a beta of 1.67.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.